

Published in final edited form as:

Aldrichimica Acta. 2009 ; 42(1): 17–27.

Iterative Cross-Coupling with MIDA Boronates: Towards a General Platform for Small Molecule Synthesis

Eric P. Gillis and Martin D. Burke

1. Introduction

Most organic molecules are inherently modular in their constitution. With respect to the molecules found in living systems, this modularity is a direct consequence of the fact that nearly all biosynthetic systems are based on the iterative coupling of bifunctional building blocks.ⁱ For example, polypeptides are built from amino acids, oligonucleotides are derived from nucleotide monomers, and oligosaccharides are stitched together from individual sugar units. Interestingly, most *small molecule* natural products are similarly constructed via the iterative coupling of bifunctional building blocks, e.g., polyketides from malonyl-CoA or methylmalonyl-CoA units, non-ribosomal peptides from amino acids, polyterpenes from isopentenyl pyrophosphate or dimethylallyl pyrophosphate, and fatty acids from malonyl-CoA.ⁱ Similarly, many man-made pharmaceuticals are also highly modular because they are constructed by using different reactions to assemble collections of small building blocks, typically cyclic and heterocyclic fragments and their associated appendages. Thus, modularity appears to be a remarkably general feature of many of the molecules that are targeted for synthesis in the laboratory.

Despite this common modularity, the strategies utilized for making polypeptides, oligonucleotides, and oligosaccharides are very different than those typically used to prepare small molecules. Specifically, all of the former classes of compounds are almost always constructed via iterative coupling of suitably-protected forms of their constituent monomers.ⁱⁱ Organic polymers are similarly prepared in this fashion.ⁱⁱⁱ Due to the powerfully simple nature of this iterative coupling approach, these processes are now increasingly performed in a fully-automated fashion.ⁱⁱⁱⁱⁱ With peptides and oligonucleotides, the advanced development of such automation has made it possible for even non-chemists to routinely prepare these types of compounds for a wide range of applications.

In stark contrast, it is typical for a synthetic chemist to develop a unique, customized strategy for each small molecule that is targeted for preparation in the laboratory. As a result, the synthesis of small molecules remains a relatively complex, unsystematized, and inflexible process practiced almost exclusively by highly trained specialists. Driven by the hypothesis that the inherent modularity in small molecules remains largely underutilized, we have established a research program that aims to develop a unified strategy for the construction of these compounds via the iterative coupling of bifunctional building blocks.^{iv}^v^{vi}^{vii} Specifically, we have targeted the development of building blocks representing substructures that appear frequently in natural products and man-made pharmaceuticals and the chemistry that will enable their precise union via iterative, metal-mediated cross-coupling reactions. In the idealized form of this envisioned “iterative cross-coupling” (ICC) approach, building blocks having all of the required functional groups preinstalled in the correct oxidation state and with the desired stereochemical relationships are iteratively united using only a single, stereospecific cross-coupling reaction (Figure 1). In addition to being simple, efficient, and potentially amenable to automation, the

modularity of this approach makes it inherently well-suited for generating diverse collections of compounds simply by substituting modified building blocks into the same synthesis pathway. It is anticipated that the advanced development of this ICC strategy will substantially enable the laboratory synthesis of a wide range of natural products, pharmaceuticals, and organic materials, and may even extend the power of small molecule synthesis to the non-chemist.

As described in this review, *N*-methyliminodiacetic acid (MIDA) boronates^{viii} represent a highly promising platform for this type of synthesis strategy. These building blocks are remarkably convenient to prepare, analyze, purify, and store. The MIDA boronate functional group is also stable to anhydrous cross-coupling conditions but easily hydrolyzed with mild aqueous base, thereby enabling the controlled, ICC of B-protected “haloboronic acids.”^{iv·v·vi} In addition, MIDA boronates are remarkably stable to a wide range of common reaction conditions and chromatography, which makes possible the facile preparation of complex borane building blocks from simple MIDA boronate starting materials via multistep synthesis.^{vi·vii} Importantly, many MIDA boronate building blocks are now commercially-available worldwide from Sigma-Aldrich (www.sigmaaldrich.com/mida). This review aims to enable the effective utilization of this platform and the ICC strategy to promote the simple, efficient, and flexible construction of small molecules.

2. Synthesis of MIDA boronates

N-Methyliminodiacetic acid^{ix} (Figure 2) is non-toxic, biodegradable,^x and commercially-available.^{xi} It can also be conveniently and efficiently synthesized on large scale for trivial cost^{xii} from the commodity chemical iminodiacetic acid.^{xiii}

Four different methods for the synthesis of MIDA boronates are shown in Table 1. Many boronic acids can be easily transformed into the corresponding MIDA boronates simply via condensation with MIDA under Dean-Stark conditions (Table 1, entry 1).^{viii·iv·vi} The removal of water by a variety of alternative techniques (e.g., molecular sieves, azeotropic drying with CH₃CN, etc.) can also promote full conversion to the MIDA boronate product. Typically this process requires heating to at least 40 °C, and the use of DMSO as a co-solvent is required to partially dissolve the MIDA ligand. Alkenyl MIDA boronates can be synthesized via a bromoboration of an alkyne to form the corresponding dibromoborane followed by trapping with MIDA in the presence of 2,6-lutidine (Table 1, entry 2).^v Alternatively, a one-pot procedure has been developed in which organotrimethylsilanes can be converted directly into MIDA boronates via transmetalation with BBr₃ followed by trapping with the disodium salt of MIDA (Table 1, entry 3).^{vii} This approach was employed in the efficient synthesis of vinyl MIDA boronate (**9**) where condensation of MIDA with the related vinyl boronic acid or vinylboronate species failed. In addition, a variety of olefins can be transformed directly to alkenyl MIDA boronates via cross-metathesis with vinyl MIDA boronate (Table 1, entry 4).^{vii} This approach avoids boronic acid intermediates and is notable for its generality, efficiency, and mildness. Moreover, in contrast to previous reports involving the use of vinyl or propenyl pinacol boronic esters,^{xiv} cross-metathesis with vinyl MIDA boronate yields only the *E* isomer and the products are uniformly compatible with silica gel chromatography (*vide infra*).

3. Physical properties of MIDA boronates

MIDA boronates possess a number of highly enabling physical properties that make them attractive as a platform for ICC and as convenient alternatives to boronic acids and esters for a wide range of other applications. Specifically, MIDA boronates are monomeric, free-

flowing, crystalline solids which are stable to storage on the benchtop under air. MIDA boronates are also universally compatible with silica gel chromatography, allowing facile purification and convenient reaction monitoring by TLC.^{iv·v·vi·vii} If the goal is to separate different MIDA boronates of similar polarity, a ternary eluent of hexanes:EtOAc and up to 10% methanol is most effective. With these conditions, we have found that even diastereomeric mixtures of MIDA boronates can be resolved. For the purification of non-polar MIDA boronates hexanes:EtOAc is an effective eluent. Additionally, acetic acid is generally compatible as a co-eluent in most solvent mixtures. Dichloromethane:methanol is a useful eluent for TLC analysis, but some decomposition of the MIDA boronates can occur if this eluent is used for preparative chromatography. Similarly, MIDA boronates should not be left to stand in solutions containing alcohols for more than an hour.

This compatibility with silica gel chromatography and the facility with which MIDA boronates can be formed from the corresponding boronic acids, makes it possible to utilize MIDA boronate formation/purification as a powerful tool to generate high purity boronic acids from crude mixtures containing many non-boronic acid byproducts. Specifically, we have found that adding a small excess of MIDA to a crude mixture of boronic acid and performing a Dean-Stark complexation leads to the formation of the corresponding MIDA boronate, while the other impurities remain largely unchanged. If the boronic acid is desired, a simple hydrolysis of the purified MIDA boronate with 1M aqueous NaOH followed by extraction of the boronic acid into an organic solvent yields the boronic acid in very pure form.

MIDA boronates are also easily purified by crystallization. A generally effective strategy is to dissolve the crude MIDA boronate in a minimum volume of acetone at 23 °C and then slowly add Et₂O until the solution becomes cloudy. Crystals usually begin to form within several minutes. Additional Et₂O should be added periodically to the mixture to re-establish the cloud-point. The crystallization is complete when the addition of Et₂O no longer clouds the solution. Alternative crystallization solvents include acetonitrile:Et₂O and EtOAc:Et₂O. X-ray quality crystals are conveniently prepared via vapor diffusion of petroleum ether into an acetone solution of the MIDA boronate.

Another important feature of MIDA boronates is that they are soluble in many organic solvents. Reactions are typically performed using THF, dioxane, dichloromethane, DMF, toluene, DMSO, acetonitrile, acetone, or 1,2-dichloroethane. Prolonged exposure of MIDA boronates to aqueous conditions or alcoholic solvents leads eventually to hydrolysis of the MIDA ligand, and this effect is accelerated with heating or in the presence of base. However, water or alcoholic solvents have been successfully employed as co-solvents in some reactions with MIDA boronates. Further, MIDA boronates are generally compatible with aqueous extractions employing water, brine, aqueous acids (e.g., aq. HCl or NH₄Cl), and even some oxidative or reductive aqueous solutions (e.g., aq. H₂O₂ at pH < 6 or aq. NaS₂O₃). Remarkably, even saturated aqueous NaHCO₃ is tolerated in the absence of alcoholic solvents. Aqueous extractions are typically performed with EtOAc or dichloromethane as an organic phase. For highly polar MIDA boronates, solvent mixtures of EtOAc:acetone or THF:Et₂O are convenient. As described below, despite this widespread stability, MIDA boronates are easily hydrolyzed to yield the corresponding boronic acids using very mild aqueous basic reagents at 23 °C.

Interestingly, in contrast to MIDA boronates such as **3**, similarly pyramidalized *N*-methyldiethanolamine adducts such as **12** (Figure 3) are not stable to silica gel. As described below, again in contrast to the MIDA boronates, *N*-methyldiethanolamine adducts are reactive under cross-coupling and many other common reaction conditions.^{iv·vi·xv} The remarkable (and in many cases unique) stability of MIDA boronates to storage under air,

chromatography, aqueous work-ups, as well as cross-coupling and many other reaction conditions (vide infra) is attributed to the extreme conformational rigidity of the fused bicyclic [*N*-methyliminodiacetate-*O,O'*,*N*]borane framework. Specifically, as shown in Figure 3, variable temperature NMR experiments with a DMSO solution of **3** reveal no coalescence of the diastereotopic methylene protons of the MIDA backbone, even at 150 °C.^{vi·xvi} In contrast, the same experiment with **12** reveals coalescence of the diastereotopic methylene protons of the diethanolamine backbone over a temperature range of 23 to 60 °C.^{vi·xvi} These studies are consistent with the conclusion that the potentially reactive boron p orbital and nitrogen lone pair of MIDA boronates are kinetically inaccessible at <150 °C.

4. Iterative Cross-Coupling (ICC) with halo MIDA boronates

The now routinely automated process of iterative peptide couplingⁱⁱ represents an inspiring benchmark for a potentially general strategy for making molecules in the laboratory. It is interesting to note that peptides are quite complex in structure, having many different functional groups with varied oxidation states and a large number of stereogenic centers. However, the synthesis of peptides is very simple, involving the use of a single reaction to iteratively assemble a collection of bifunctional building blocks having all of the required functional groups and stereochemistry preinstalled. With the goal of developing an analogous process for the laboratory construction of small molecules, we decided to focus on the Suzuki-Miyaura reaction and the ICC of bifunctional “haloboronic acids” (Figure 1).

To avoid random oligomerization of a haloboronic acid under cross-coupling conditions, it was necessary to find a way to reversibly attenuate the reactivity of one end of this type of bifunctional reagent, analogous to the use of a protective group to control the reactivity of the amine terminus of an amino acid.^{xvii} Toward this goal, we chose to focus on controlling the reactivity of a boronic acid.

It is hypothesized that a vacant and Lewis acidic boron p-orbital is required for transmetalation of a boronic acid under Suzuki-Miyaura cross-coupling conditions (Figure 4A).^{xviii} Consistent with this, complexation with electron-donating, Lewis basic ligands is known to attenuate the reactivity of boronic acids towards cross-coupling (Figure 4B).^{xviii} For example, pinacol boronic esters can be less reactive than the corresponding boronic acids under anhydrous coupling conditions.^{xix} This reactivity attenuation can be attributed to the decreased Lewis acidity of the boron p-orbital via conjugation with the ligand heteroatom lone pairs.^{xviii} This same approach has been utilized with a variety of other divalent heteroatomic ligands.^{xx} There is an inherent limitation, however, that precludes the general utilization of this approach for complex small molecule synthesis. Specifically, conjugation between the heteroatom lone pairs and the boron p orbital creates relatively strong boron-heteroatom bonds, creating a high kinetic barrier for bond cleavage. Moreover, the equilibrium between the boronic acid and the corresponding boronic ester typically lies strongly towards the latter, creating an additional thermodynamic barrier to hydrolysis. As a result, cleaving these types of ligands to regenerate the boronic acid typically requires harsh conditions^{xviii·xix·xx} and/or additional reagents to destroy the divalent ligand after it has been cleaved.^{xxi} These types of conditions can be problematic in the context of complex small molecule synthesis.

Recognizing the inherent limitations of this approach, we focused on an alternative strategy (Figure 4C).^{iv} Given that the boron p-orbital is predicted to be critical for transmetalation of a boronic acid, we hypothesized that removing this p-orbital via rehybridizing an sp²-hybridized boronic acid to its sp³-hybridized boronate via complexation with a trivalent heteroatomic ligand would eliminate reactivity towards cross-coupling. Further increasing our interest in this approach, it is known that boron-heteroatom bonds in tetrahedral adducts

are weaker than those in their tricoordinate counterparts.^{xxii} For example, the pyramidalization of trimethyl borate via complexation with ammonia actually *weakens* the boron-oxygen bonds by about 10–12 kcal/mol.^{xxiii} Thus, we felt that it might be possible to find relatively mild conditions that could hydrolyze this type of pyramidalized boronate and regenerate the reactive boronic acid. After surveying a series of trivalent heteroatomic ligands, we discovered that MIDA boronates embody all of these expectations and represent a powerful platform for ICC chemistry.

Specifically, in a competition experiment between tolylboronic acid (**14b**) and *para-n*-butylphenyl MIDA boronate under Buchwald-type^{xxiv} anhydrous Suzuki-Miyaura cross-coupling conditions with *p*-bromoanisaldehyde, we observed a 24:1 ratio of products **15** and **16**, consistent with a strong preference for cross-coupling of the sp²-hybridized boronic acid.^{iv} Interestingly, a wide range of non-aryl substituents were tolerated on the nitrogen atom (e.g. Table 2, entry 2). However, the corresponding diethanolamine adduct (**14d**), lacking the carbonyl units of MIDA, was equally reactive as the boronic acid (Table 2, entry 4). As described above, this difference in reactivity is attributed to differences in conformational flexibility of these two complexes.

Encouraged by these results, we set out to prepare a series of bifunctional B-protected haloboronic acids and explore their capacity to undergo selective cross-coupling at the halide terminus. The efficient synthesis of aryl heteroaryl, alkenyl and alkyl derivatives was achieved via simple condensation of the corresponding boronic acids with MIDA under Dean-Stark conditions (Scheme 1). As shown in Table 3, this approach proved to be remarkably general, with the same ligand similarly protecting aryl, heteroaryl, alkenyl and alkyl boronic acids. Moreover, consistent with our initial hypothesis, the MIDA boronate products of these reactions can all be hydrolyzed under mild aqueous basic conditions (1N aq. NaOH/THF, 23 °C, 10 min) to generate the corresponding reactive boronic acid.

Polyenes are especially challenging synthetic targets because of the sensitivity of this framework to light, oxygen, and acid. It is also critical to control the stereochemistry of each double bond. The ICC approach is particularly well-suited to making these types of compounds due to the mild and stereospecific nature of metal-mediated cross-coupling. Given the prevalence of akenyl and polyenyl subunits in both natural products and pharmaceutical targets, we developed a collection of bifunctional building blocks specifically designed to enable polyene synthesis via ICC.^v

As described in Table 1, *trans*-(2-bromovinyl) MIDA boronate **7** can be prepared via bromoboration of acetylene^{xxv} followed by complexation with MIDA in the presence of 2,6-lutidine. An alternative and more convenient procedure involves transmetalation of 1-bromo-2-(trimethylsilyl)ethylene with BBr₃^{xxvi} followed by trapping with MIDA²⁻Na⁺₂.^{vii} This building block has proven to be a remarkably versatile cross-coupling partner (Scheme 2).^v Specifically, Suzuki-Miyaura, Stille, and Heck couplings were all achieved at the bromide terminus without perturbing the MIDA boronate. A series of bis-metallated lynchpin-type reagents were also created via Sonogashira coupling with TMS acetylene, Miyaura borylation with pinacolatodiborane **25**, and a triply metal-selective (Zn vs. Sn and B) Negishi coupling with bismetallated olefin **27**.

In the first example of boron-selective coupling of a differentially-ligated bis-borylated building block, **26** was selectively coupled with *trans*-1-chloro-2-iodoethylene at the sp²-hybridized pinacol boronic ester terminus to generate chlorodienyl MIDA boronate **29** (Scheme 3). This type of boron-selective coupling of differentially-ligated diboron reagents has the potential to be a generally useful strategy.^{xxvii} A more well-precedented Sn vs B

coupling^{xxviii} between *bis*-metallated diene **28** and *trans*-1-chloro-2-iodoethylene generated chlorotrienyl MIDA boronate **30**.

The olefin cross-metathesis route to MIDA boronates is remarkably tolerant to a wide range of functional groups, including halogens. Thus, this method is particularly well suited for preparing various haloalkenyl MIDA boronates, as shown for a series of bromostyrene derivatives in Scheme 4.vii

The capacity to prepare and selectively couple bifunctional halo MIDA boronates enables one to envision the synthesis of natural products or pharmaceuticals using only a single reaction iteratively to assemble a collection of pre-assembled building blocks. This was first demonstrated with the total synthesis of ratanhine,^{iv} a complex neolignan isolated from the *Ratanhiae radix* by Arnone and coworkers in 1990.^{xxix} This natural product was retrosynthetically fragmented using recursive Suzuki-Miyaura transforms to generate four simpler building blocks **35** – **38** (Scheme 5). There were several challenges associated with this plan that were expected to test the limits of the MIDA-based ICC methodology. First, couplings of alkenyl boronic acids tend to be less efficient than those with aryl derivatives, making the selective coupling between **35** and aryl MIDA boronate **36** unsecured. In addition, 2-substituted heterocyclic boronic acids such as **36** are notoriously unstable and difficult to purify, store, and cross-couple.^{xxx} Finally, the coupling of highly deactivated bromoaryl MIDA boronate **37** was expected to demand more forcing reaction conditions that would test the limits of stability of the MIDA boronate functionality.

Despite these challenges, the first total synthesis of ratanhine was achieved via ICC as shown in Scheme 6. Specifically, a selective coupling between propenylboronic acid **35** and bromobenzofuranyl MIDA boronate **36** proceeded smoothly to generate 2-substituted benzofuranyl MIDA boronate **39**. Remarkably, while the corresponding benzofuranyl boronic acid decomposed over the course of several days, MIDA boronate **39** was stored on the benchtop under air without noticeable decomposition for more than 6 months. This MIDA boronate was hydrolyzed under mild conditions and the resulting boronic acid was immediately utilized in a cross-coupling reaction with bromoaryl MIDA boronate **37**. As expected, this coupling required increased temperature (80 °C in a sealed tube) and extended reaction time (28 h). Remarkably, however, the MIDA boronate functional group was stable to these forcing conditions, yielding the highly conjugated MIDA boronate product **40**. A final sequence of boronic acid deprotection and coupling with alkenyl bromide **38** and MOM-ether deprotection completed the first total synthesis of this natural product. More importantly, to the best of our knowledge, this represents the first total synthesis of any natural product in which a single reaction was utilized iteratively to assemble all of the required building blocks.

This same ICC strategy has proven to be highly effective in the synthesis of polyene natural products.^v Specifically, as shown in Scheme 7, all-*trans*-retinal^{xxxi} was prepared simply via ICC of boronic acid **42**, bromoalkenyl MIDA boronate **7**, and alkenyl bromide **44**. In a similar vein, β -parinaric acid^{xxxii} was prepared via the ICC of butenylboronic acid **46**, chlorodienyl MIDA boronate **29**, and alkenyliodide **48** (Scheme 8). Finally, the notoriously challenging heptaene framework of the polyene natural product amphotericin B was prepared using only the Suzuki-Miyaura reaction to assemble a collection of bifunctional haloalkenyl MIDA boronates (Scheme 9).

Demonstrated by these examples, the ICC approach has substantial potential to enable the simple, efficient, and flexible construction of small molecules.

6. Multistep synthesis of complex boronic acids from simple MIDA boronates

To avoid a general incompatibility with synthetic reagents, it is typically necessary to introduce the boronic acid functional group just prior to its utilization in a cross-coupling or other type of reaction. However, most of the methods that are available for achieving this have poor functional group tolerance. Collectively, these limitations can render the synthesis of complex boronic acids very challenging. This can preclude the use of boronic acids in complex molecule synthesis and represents a potential bottleneck for the development of a truly general ICC-based approach.

Some sterically-bulky boronic esters are known to be more tolerant to synthetic reagents;xxxiii however, removing these ligands to generate a targeted boronic acid usually requires harsh conditions that are generally incompatible with sensitive building blocks. Trifluoroborate salts represent highly useful surrogates for boronic acidsxxxiv and are compatible with many synthetic reagents.xxxv These features have provided novel access to many new organoborane building blocks. However, the incompatibility of the trifluoroborate salts with column chromatography can limit the utilization of these reagents in multistep synthesis, which is often necessary for accessing structurally and/or stereochemically complex building blocks.

Overcoming all of these limitations, we have recently found that the MIDA boronate functional group is stable to a wide range of common synthetic reagents.vi Combined with the general compatibility of MIDA boronates with chromatography and the capacity to release the corresponding boronic acids under very mild conditions, this stability enables the first reliable approach for the multistep synthesis of complex boronic acids from simple organoborane starting materials.

Due to the absence of a reactive p-orbital on boron, we hypothesized and confirmed experimentally that the MIDA boronate functional group would be stable to mild synthetic reagents. For example, hydroxymethylphenyl MIDA boronate **3** can be smoothly oxidized under Swern conditions to generate the corresponding benzaldehyde (Scheme 10). However, we were very surprised to find that MIDA boronates are even stable to the very strongly acidic and oxidizing Jones conditions ($\text{H}_2\text{SO}_4/\text{CrO}_3$). This latter stability is highly unique; *i.e.*, under these same conditions, the corresponding boronic acid (**56a**), pinacolboronic ester (**56b**), 1,8-diaminonaphthalene adduct (**56c**), trifluoroborate salt (**56d**), and *N*-methyldiethanolamine boronatexxxvi (**56e**) all decomposed. Similar to that which we observed under cross-coupling conditions, the remarkable difference in reactivity between the MIDA and diethanolamine boronates is likely related to the differences in conformational flexibility of the two complexes (Figure 3).

This unique compatibility with strong acid and oxidants suggested that MIDA boronates could be stable to a wide range of reaction conditions. In fact, even triflic acid (pK_a -14) was tolerated, enabling the *p*-methoxybenzylation of **3** and the reversal of this transformation with DDQ (Scheme 11). Similarly silylation and desilylation were well-tolerated, as was transformation into the corresponding benzyliodide with PPh_3/I_2 .

This latter reaction suggested compatibility with soft nucleophiles. In this vein, benzaldehyde **54** was successfully utilized in a series of carbon-carbon bond forming reactions including the Evans aldol, Horner-Wadsworth-Emmons, and Takai olefination reactions. Reductive amination and aldehyde reduction were also well-tolerated (Scheme 12).

In another study, broad compatibility was also observed using vinyl MIDA boronate **9** as a versatile starting material (Scheme 13).^{vii} Specifically, cyclopropanation of **9** produced cyclopropyl MIDA boronate in excellent yield.^{xxxvii} Remarkably, epoxidation of this olefin^{xxxviii} with mCPBA was also well-tolerated and even this product was stable to column chromatography and benchtop storage under air. This same versatile building block **9** was successfully engaged in the Heck reaction^{xxxix} to yield styrenyl derivative **66** as a single stereo- and regioisomer. Similarly, the White catalyst^{xl} promoted an efficient oxidative Heck^{xli}-type reaction^{xlii} to yield **67**. As described above (Scheme 4), this same vinyl MIDA boronate building block is also an excellent substrate for olefin cross-metathesis (analogous to tert-butyl ethylene), yielding *E*-octenyl MIDA boronate **68** as air- and chromatographically stable crystalline solid and a single stereoisomer (Scheme 13). Fortunately, this approach has proven to be quite general and represents a very useful new approach to prepare a range of (*E*)-alkenyl MIDA boronates (Table 4).

This broad compatibility of the MIDA boronate functional group can enable the transformation of simple MIDA boronate starting materials into otherwise difficult to access complex boronic acids for use in a variety of synthesis applications. Specifically regarding the ICC strategy, this approach can also provide access to a wide range of structurally complex B-protected haloboronic acids.

To explore the enabling potential of this approach, we targeted the total synthesis of the natural product crocacin C^{xliii} via ICC. As shown in Scheme 14, this molecule was retrosynthesized via recursive cross-coupling reactions into known building blocks **72** and **74** as well as the unknown, complex iodoalkenyl MIDA boronate **73**. Preparation of the latter represents a significant challenge that we hypothesized could be overcome via multistep synthesis starting with simple MIDA boronate **75** (Scheme 15).

In practice, a Paterson aldol reaction between **75** and **76** followed by diastereoselective reduction of the resulting β -hydroxyketone yielded diol **77**. Importantly, the small amounts of diastereomeric byproducts that are typically generated in these types of transformations were readily removed by taking advantage of the compatibility of the MIDA boronate functional group to silica gel chromatography. A subsequent sequence of permethylation with Meerwein's salt, oxidative cleavage of the PMB ether, oxidation of the resulting primary alcohol, and Takai olefination yielded the targeted complex halo MIDA boronate **73**. Importantly, **75**, **73**, and all intermediates were compatible with chromatography and storage on the benchtop under air. With B-protected haloboronic acid **73** in hand, the synthesis of crocacin C was readily achieved via ICC (Scheme 16).

7. Prospectus

As described herein, the inherent modularity found in many of the small molecules targeted for synthesis in the laboratory stands to be more effectively harnessed via the ICC-based approach. Analogous to the synthesis of peptides, oligonucleotides, and oligosaccharides, this strategy has the potential to enable the preparation of a wide range of small molecules via the simple, iterative union of pre-assembled, bifunctional building blocks. Due to their ease of synthesis, purification, characterization, and storage, their reversibly attenuated reactivity under cross-coupling conditions, and their compatibility with a wide range of common synthetic reagents, MIDA boronates represent a powerful platform for the development of this type of synthesis strategy.

Looking forward, the ever-expanding scope of the Suzuki-Miyaura coupling suggests that the potential generality of this approach could be substantial. Particularly critical to realizing this potential will be to find a way to form Csp^3-Csp^2 and even Csp^3-Csp^3 bonds with the

same efficiency and stereospecificity that is now routinely achieved with Csp^2 – Csp^2 linkages. The discovery of additional methods to prepare MIDA boronates that do not proceed through the intermediacy of a difficult to access and/or unstable boronic acid will also be vital. Moreover, to realize the ultimate goal of developing a machine with the capacity for fully-automated ICC, it will be important to identify Suzuki-Miyaura cross-coupling conditions that are maximally general^{xxiv} (to avoid the requirement for ad hoc optimization of conditions for each combination of coupling partners) and amenable to translation to the solid-phase or some other form of iterative synthesis enabling technology. While these challenges are admittedly considerable, we are convinced that they each can be solved. Achieving these goals could have a substantial impact on the synthesis of small molecules in the laboratory and may ultimately even expand the power of this discovery engine to the non-chemist.


References

- i. (a) Fischbach MA, Walsh CT. *Chem. Rev.* 2006; 106:3468–3496. [PubMed: 16895337] (b) Garret; Grisham. *Biochemistry*. Saunders College Publishing; 1995.
- ii. (a) Merrifield RB. *Angew Chem. Int. Ed.* 1985; 24:799. (b) Caruthers MH. *Science*. 1985; 230:281. [PubMed: 3863253] (c) Plante OJ, Palmacci MR, Seeberger PH. *Science*. 2001; 291:1523. [PubMed: 11222853]
- iii. (a) Zhang J, Moore JS, Xu Z, Aguirre RA. *J. Am. Chem. Soc.* 1992; 114:2273–2274. (b) Young JK, Nelson JC, Moore JS. *J. Am. Chem. Soc.* 1994; 116:10841–10842. (c) Feuerbacher N, Vogtle F. *Topics in Current Chemistry*. 1998; 197:1–16.
- iv. Gillis EP, Burke MD. *J. Am. Chem. Soc.* 2007; 129:6716–6717. [PubMed: 17488084]
- v. Lee SJ, Gray KC, Paek JS, Burke MD. *J. Am. Chem. Soc.* 2008; 130:466–468. [PubMed: 18081295]
- vi. Gillis EP, Burke MD. *J. Am. Chem. Soc.* 2008; 130:14084–14085. [PubMed: 18837550]
- vii. Uno BE, Gillis EP, Burke MD. *Tetrahedron*. 2009 *In Press* (DOI 10.1016/j.tet.2008.11.010).
- viii. (a) Mancilla T, Contreras R, Wrackmeyer B. *J. Organomet. Chem.* 1986; 307:1–6. (b) Mancilla T, coworkers. *Arkivoc*. 2005:366–376.
- ix. (a) Berchet GJ. *Org. Syn.* 1938; 18:56. (b) Childs AF, Goldsworthy LJ, Harding GF, King FE, Nineham AW, Norris WL, Plant SGP, Selton B, Tompsett ALL. *J. Chem. Soc.* 1948:2174–2177. (c) Chase BH, Downes AM. *J. Chem. Soc.* 1953:3874–3877.
- xx. Warren CB, Malec EJ. *Science*. 1972; 176:277–279. [PubMed: 5019779]
- xi. Aldrich: M51008
- xii. Ballmer SG, Gillis EP, Burke MD. submitted.
- xiii. Tens of thousands of metric tons of iminodiacetic acid is produced annually worldwide: Yangong Z. *China Chemical Reporter*. 2005:16..
- ivx. (a) Blackwell HE, O’Leary DJ, Chatterjee AK, Washenfelder RA, Busmann AA, Grubbs RH. *J. Am. Chem. Soc.* 2000; 122:58–71. (b) Morrill C, Grubbs RH. *J. Org. Chem.* 2003; 68:6031–6034. [PubMed: 12868943] (c) Njardarson JT, Biseas K, Danishefsky SJ. *Chem. Commun.* 2002; 23:2759–2761. (d) Nicolaou KC, Li A, Edmonds DJ. *Angew. Chem. Int. Ed.* 2006; 45:7086–7090. (e) Jankowska M, Pietraszuk C, Marciniec B, Zaidlewicz M. *SynLett.* 2006; 11:1695–1698. (f) Dakas PY, Barluenga S, Totzke F, Zirrgiebel U, Winssinger N. *Angew. Chem. Int. Ed.* 2007; 46:6899–6902. (g) Wu T, Gao J. *Org. Lett.* 2008; 10:1533–1536. [PubMed: 18338900] Ring Closing Metathesis reactions: (h) Ashe AJ III, Fang X, Kampf JW. *Organometallics*. 2000; 19:4935–4937. (i) Ashe AJ III, Hong Y, Fang X, Kampf JW. *Organometallics*. 2002; 21:4578–4580..
- xv. For some important exceptions, see: (a) Ebdrup S, Jacobsen P, Farrington AD, Vedso P. *Bioorg. Med. Chem.* 2005; 13:2305–2312. [PubMed: 15727879] (b) Vedso P, Olesen PH, Hoeg-Jensen T. *Synlett*. 2004; 5:892–894. (c) Kirihata M, Morimoto T, Mizuta T, Ichimoto I. *Bioscience, Biotechnology, and Biochemistry*. 1995; 59:2317–2318. (d) Kirihara M, Morimoto T, Ichimoto I. *Bioscience, Biotechnology, and Biochemistry*. 1993; 57:1940–1941. (e) Yamamoto Y, Seko T, Rong FG, Nemoto H. *Tetrahedron Lett.* 1989; 30:7191–7194..

- xvi. These results are consistent with previous studies: (a) Ref 8, (b) Psarras TG, Zimmerman HK, Rasiel Y, Weidman H. *Liebigs Ann. Chem.* 1962; 655:48–54. (c) Contreras R, García C, Mancilla T, Wrackmeyer B. *J. Organomet. Chem.* 1983; 246:213–217..
- xvii. (a) Bergmann M, Zervas L. *Ber. Dtsch. Chem. Ges.* 1932; 65:1192. (b) Carpino LA, Han GY. *J. Am. Chem. Soc.* 1970; 92:5748. (c) Tarbell DS, Yamamoto Y, Pope BM. *Proc. Nat. Acad. Sci. USA.* 1972; 69:730–732.
- xviii. (a) Matos K, Soderquist J. *J. Org. Chem.* 1998; 63:461–470. [PubMed: 11672034] (b) Miyaura N. *J. Organomet. Chem.* 2002; 653:54–57. (c) Braga AAC, Morgon NH, Ujaque G, Maseras F. *J. Am. Chem. Soc.* 2005; 127:9298–9307. [PubMed: 15969613]
- xix. (a) Holmes D, Chotana GA, Maleczka RE Jr, Smith MR III. *Org. Lett.* 2006; 8:1407–1410. [PubMed: 16562903] (b) Gillis EP, Burke MD. unpublished results.
- xx. (a) Deng X, Mayeux A, Cai C. *J. Org. Chem.* 2002; 67:5279–5283. [PubMed: 12126416] (b) Hohn E, Pietruszka J. *Adv. Synth. Catal.* 2004; 346:863–866. (c) Noguchi H, Hojo K, Suginoe M. *J. Am. Chem. Soc.* 2007; 129:758–759. [PubMed: 17243801]
- xxi. (a) Nakamura H, Fujiwara M, Yamamoto Y. *Bulletin of the Chemical Society of Japan.* 2000; 73:231–235. (b) Falck JR, Bondlela M, Venkataraman SK, Srinivas D. *J. Org. Chem.* 2001; 66:7148–7150. [PubMed: 11597243] (c) Murphy JM, Tzschucke CC, Hartwig JF. *Org. Lett.* 2007; 9:757–760. [PubMed: 17274623]
- xxii. Hall, DG. *Boronic Acids.* Germany: Wiley-VCH; 2005. p. 3-14.
- xxiii. Matteson, DS. *Stereodirected Synthesis with Organoboranes.* Berlin: Springer; 1995. p. 1-20.
- xxiv. (a) Barder TE, Walker SD, Martinelli JR, Buchwald SL. *J. Am. Chem. Soc.* 2005; 127:4685–4696. [PubMed: 15796535] (b) Billingsley K, Buchwald SL. *J. Am. Chem. Soc.* 2007; 129:3358–3366. [PubMed: 17326639] (c) Ruben M, Buchwald SL. *Acc. Chem. Res.* 2008; 41:1461–1473. [PubMed: 18620434]
- xxv. Hyuga S, Chiba Y, Yamashina N, Hara S, Suzuki A. *Chem. Lett.* 1987:1757–1760.
- xxvi. Singleton DA, Leung SW. *J. Organomet. Chem.* 1997; 544:157–161.
- xxvii. For some recent additional examples, see: (a) Molander GA, Sandrock DL. *J. Am. Chem. Soc.* 2008; 130:15792–15793. [PubMed: 18980313] (b) Noguchi H, Shioda T, Chou C-M, Suginoe M. *Org. Lett.* 2008; 10:377–380. [PubMed: 18183990] .
- xxviii. (a) Coleman RS, Walczak MC. *Org. Lett.* 2005; 7:2289–2291. [PubMed: 15901191] (b) Coleman RS, Lu X, Modolo I. *J. Am. Chem. Soc.* 2007; 129:3826–3827. [PubMed: 17358066]
- xxix. Arnone A, coworkers. *Gazzetta Chimica Italiana.* 1990; 120:397.
- xxx. Tyrell E, Brookes P. *Synthesis.* 2003; 4:469–483.
- xxxi. Previous cross-coupling-based syntheses of retinoids: (a) Negishi E, Owczarczyk Z. *Tetrahedron Lett.* 1991; 32:6683–6686. (b) ref 13b. (c) Uenishi J, Kawahama R, Yonemitsu O, Wada A, Ito M. *Angew. Chem. Int. Ed.* 1998; 37:320–323. (d) Uenishi J, Matsui K, Wada A. *Tetrahedron Lett.* 2003; 44:3093–3096..
- xxxii. Some prior syntheses of β -parinaric acid: (a) Kuklev DV, Smith WL. *Chem. Phys. Lipids.* 2004; 131:215–222. [PubMed: 15351273] (b) Goerger MM, Hudson BS. *J. Org. Chem.* 1988; 53:3148–3153. (c) Hayashi T, Oishi T. *Chem. Lett.* 1985:413–416..
- xxxiii. (a) Matteson DS, Kandil AA, Soundararajan R. *J. Am. Chem. Soc.* 1990; 112:3964–3969. (b) Matteson DS, Man H-W, Ho OC. *J. Am. Chem. Soc.* 1996; 118:4560–4566. (c) Luthle JEA, Pietruszka J. *J. Org. Chem.* 2000; 65:9194–9200. [PubMed: 11149869] (d) Hilt G, Bolze P. *Synthesis.* 2005; 13:2091–2115. (e) Jin B, Liu Q, Sulikowski GA. *Tetrahedron.* 2005; 61:401–408. (f) Gopalarathnam A, Nelson SG. *Org. Lett.* 2006; 8:7–10. [PubMed: 16381554]
- xxxiv. (a) Molander GA, Ellis N. *Acc. Chem. Res.* 2007; 40:275–286. [PubMed: 17256882] (b) Darses S, Genet J-P. *Chem. Rev.* 2008; 108:288–325. [PubMed: 18095714]
- xxxv. (a) Molander GA, Petrillo DE. *J. Am. Chem. Soc.* 2006; 128:9634–9635. [PubMed: 16866509] (b) Molander GA, Ribagorda M. *J. Am. Chem. Soc.* 2003; 125:11148–11149. [PubMed: 16220907] (c) Molander GA, Petrillo DE. *Org. Lett.* 2008; 10:1795–1798. [PubMed: 18393522] (d) Molander GA, Gormisky PE, Sandrock DL. *J. Org. Chem.* 2008; 73:2052–2057. [PubMed: 18284257] (e) Pucheault M, Darses S, Genet J-P. *J. Am. Chem. Soc.* 2004; 126:15356–15357. [PubMed: 15563143]

- xxxvi. (a) Vedso P, Olesen PH, Hoeg-Jensen T. *Synlett*. 2004;892–894. (b) Gravel M, Thompson KA, Zak M, Bérubé C, Hall DG. *J. Org. Chem.* 2002; 67:3–15. [PubMed: 11777432]
- xxxvii. Previous cyclopropanations with vinyl boranes: (a) Fontani P, Carboni B, Vaultier M, Carrié R. *Tetrahedron Lett.* 1989; 30:4815–4818. (b) Fontani P, Carboni B, Vaultier M, Maas G. *Synthesis*. 1991; 8:605–609.
- xxxviii. Previous epoxidation of 1,2-disubstituted alkenyltrifluoroborate salts: Molander GA, Ribagorda M. *J. Am. Chem. Soc.* 2003; 125:11148–11149. [PubMed: 16220907]
- xxxix. Heck reactions with vinyl boranes: (a) Hunt AR, Stewart SK, Whiting A. *Tetrahedron Lett.* 1993; 482:3599–3602. (b) Stewart SK, Whiting A. *J. Organomet. Chem.* 1994; 482:293–300. (c) Lightfoot AP, Maw G, Thirsk C, Twiddle S, Whiting A. *Tetrahedron Lett.* 2003; 44:7645–7648. (d) Stewart SK, Whiting A. *Tetrahedron Lett.* 1995; 36:3925–3928. (e) Hénaff N, Whiting A. *Org. Lett.* 1999; 1:1137–1139. (f) Hénaff N, Whiting A. *Tetrahedron*. 2000; 56:5193–5024. (g) Lightfoot AP, Twiddle SJR, Whiting A. *Org. Biomol. Chem.* 2005; 3:3167–3172. [PubMed: 16106297] (h) Batsanov AS, Knowles JP, Whiting A. *J. Org. Chem.* 2007; 72:2525–2532. [PubMed: 17335239] (i) Itami K, Tonogaki K, Nokami T, Ohashi Y, Yoshida J. *Angew. Chem. Int. Ed.* 2006; 45:2404–2409. (j) Itami K, Tonogaki K, Ohashi Y, Yoshida J. *Org. Lett.* 2004; 6:4093–4096. [PubMed: 15496107].
- xl. (a) Chen MS, White MC. *J. Am. Chem. Soc.* 2004; 126:1346–1347. [PubMed: 14759185] (b) Chen MS, Prabakaran N, Labenz NA, White MC. *J. Am. Chem. Soc.* 2005; 127:6970–6971. [PubMed: 15884938] (c) Fraunhofer KJ, Prabakaran N, Sirois LE, White MC. *J. Am. Chem. Soc.* 2006; 128:9032–9033. [PubMed: 16834366] (d) Fraunhofer KJ, White MC. *J. Am. Chem. Soc.* 2007; 129:7274–7276. [PubMed: 17516648] (e) Reed SA, White MC. *J. Am. Chem. Soc.* 2008; 130:3316–3318. [PubMed: 18302379] (f) Young A, White MC. *J. Am. Chem. Soc.* 2008 *ASAP*.
- xli. (a) Cho CS, Uemura S. *J. Organomet. Chem.* 1994; 465:85–92. (b) Du X, Suguro M, Hirabayashi K, Mori A, Nishikata T, Hagiwara N, Kawata K, Okeda T, Wang H, Fugami K, Kosuhi M. *Org. Lett.* 2001; 3:3133. [PubMed: 11574013] (c) Yoo KS, Yoon CH, Jung KW. *J. Am. Chem. Soc.* 2006; 128:16384. [PubMed: 17165795] (d) Lindh J, Enquist PA, Pilotti A, Nilsson P, Larhed M. *J. Org. Chem.* 2007; 72:7957–7962. [PubMed: 17887706]
- xlii. (a) Delcamp JH, White MC. *J. Am. Chem. Soc.* 2006; 128:15076–15077. [PubMed: 17117844] (b) Delcamp JH, Brucks AP, White MC. *J. Am. Chem. Soc.* 2008; 130:11270–11271. [PubMed: 18671350]
- xliii. (a) Kunze B, Jansen R, Hofle G, Reichenbach H. *J. Antibiot.* 1994; 47:881–886. [PubMed: 7928674] Previous syntheses: (b) Dias LC, de Oliveira LG. *Org. Lett.* 2001; 3:3951–3954. [PubMed: 11720577] (c) Chakraborty TK, Jayaprakash S. *Tetrahedron Lett.* 2001; 42:497–499. (d) Feutrill JT, Lilly MJ, Rizzacasa MA. *Org. Lett.* 2000; 2:3365–3367. [PubMed: 11029212] (e) Sirasani G, Paul T, Andrade RB. *J. Org. Chem.* 2008; 73:6386–6388. [PubMed: 18630880].

Iterative peptide coupling



Iterative cross-coupling




Figure 1.
Analogous strategies for the synthesis of peptides and small molecules.




Figure 2.
N-Methyliminodiacetic acid (MIDA)




Figure 3. Variable temperature NMR studies with MIDA boronate and N-methyldiethanolamine adducts that demonstrate the unique and remarkable conformational rigidity of the MIDA boronate framework.






Figure 4.

A. Transmetalation in the Suzuki-Miyaura reaction requires a vacant and Lewis acidic p-orbital. **B.** Strongly electron-donating divalent ligands can attenuate boronic acid reactivity but typically require relatively harsh conditions for cleavage. **C.** The reactivity of a boronic acid can be reversibly attenuated with a trivalent ligand.




^aYields are shown in parentheses and refer to *analytically pure* materials obtained conveniently via silica gel chromatography. ^bCrystallized from THF.


Scheme 1.




Scheme 2.




Scheme 3.




Scheme 4.




Scheme 5.





Scheme 7.




Scheme 8.




Scheme 9.




Scheme 10.




Scheme 11.




Scheme 12.




Scheme 13.



Scheme 14.



Scheme 15.



Scheme 16.

Table 1

Currently-available methods for the synthesis of MIDA boronates













Table 2

Trivalent N-alkyliminodiacetic acid ligands attenuate the reactivity of boronic acids.

Entry		15 : 16*
1	 14a	24 : 1.0
2	 14b	1.0 : 1.0
3	 14c	25 : 1.0
4	 14d	1.0 : 1.0

	13 (1 equiv.)	+		15
				
			K₃PO₄, THF 65 °C, 6 h	
	14 (1 equiv.)			16

* HPLC, average of three runs.

Table 3

The general use of halo MIDA boronates in ICC

Entry	18	Protected product	Deprotected product	% Yield	% Yield
1	18a			87	86
2	18b			85	92
3	18c			80	97 ^a
4 ^b	18d			81	88
5	18e			82	83
6	18f			94	91

^aB-Deprotection was also achieved via treatment with saturated aq. NaHCO₃/MeOH, 23 °C, 6 hours (85%).

^b2-(Dicyclohexylphosphino)-2,4,6-triisopropyl-1,1'-biphenyl (X-Phos) was used as the phosphine ligand.

Table 4

Entry	cross partner	cross product	isolated yield (%)
1	69a	70a	85
2	69b	70b	84
3	69c (<i>E:Z</i> 1:1)	70c	98
4	69d	70d	96
5	69e	70e	94
6	69f	67	93